We strive to advance new treatment options that are potentially safe, effective, and convenient for patients suffering from debilitating autoimmune diseases.

Tenet Medicines, Inc., is a biopharmaceutical company focused on developing therapeutics for autoimmune diseases. Tenet’s lead program, TNT119, also known as budoprutug, is an anti-CD19 monoclonal antibody designed to target and deplete autoantibody-secreting B-cells. TNT119 is being developed for inflammatory indications with high unmet medical needs, including systemic lupus erythematosus (“SLE”), immune thrombocytopenia (“ITP”), and membranous nephropathy (“MN”).